Therefore, we suppose that NKG2D-CAR T cells expressing IL-7 would have the capacity to persist in the immuno-suppressive microenvironment in prostate cancer tissues and induce potent antitumor immunity in patients, but more evidence is needed. Here, IL7 is linked to prostate carcinoma.